DXCM vs PCRX
DXCM: Dexcom is a leading medical technology company specializing in continuous glucose monitoring (CGM) systems that help people with diabetes manage their condition with real-time data. PCRX: Pacira BioSciences is a specialty pharmaceutical company focused on developing non-opioid pain management solutions to improve the postsurgical patient experience.
Side-by-side fundamentals
| Metric | DXCM | PCRX | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $84.41 | $36.39 | |
| Market cap | $31.9B | $1.5B | |
| P/E as of 2026-10-08 | 33.60 | 104.84 | DXCM lower |
| PEG as of 2026-10-08, 3-year EPS CAGR to FY2025 | 0.92 | n/a | |
| Net margin FY2025, SEC XBRL | +17.9% | +1.0% | DXCM higher |
| Gross margin FY2025, SEC XBRL | +60.1% | n/a | |
| Operating margin FY2025, SEC XBRL | +19.6% | +2.6% | DXCM higher |
| ROE FY2025, SEC XBRL | +30.5% | +1.0% | DXCM higher |
| ROA FY2025, SEC XBRL | +13.2% | +0.6% | DXCM higher |
| Debt / equity as of 2026-09-03 | 0.49 | 0.54 | DXCM lower |
| Revenue growth (YoY) as of 2026-09-03 | +15.5% | +5.7% | DXCM higher |
| Revenue CAGR (3y) SEC XBRL | +17.0% | +2.9% | DXCM higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 0.89 | 0.23 | |
| 1-year return as of 2026-10-08 close | +24.5% | +55.4% | PCRX higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.